

Lion Biotechnologies to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

September 5, 2014 12:38 PM ET

LOS ANGELES, Sept. 5, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor). The conference is being held at The New York Palace Hotel from September 8-10, 2014.

A webcast of Dr. Singh's presentation will be available both live and on replay. The presentation will be available via webcast at <http://wsj.com/webcast/rrshq24/lbio>. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of Lion Biotechnologies' presentation will also be accessible via the Investors section of the Company's web site at <http://lbio.com/investors/> under "Recent Events."

About Lion Biotechnologies

Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit <http://www.lionbio.com>.

CONTACT: Investor Relations
The Trout Group
Gitanjali Jain Ogawa
646-378-2949
gogawa@troutgroup.com

Source: Lion Biotechnologies, Inc.

Released September 5, 2014